Patients suffering from psoriatic arthritis often report pain and fatigue. Previous studies have demonstrated improvements in pain and fatigue for up to 2 years with ixekizumab in patients who had an inadequate response or intolerance to tumour necrosis factor inhibitors (TNFi). At the EULAR 2020 meeting, Prof. Ana-Maria Orbai (Johns Hopkins University School of Medicine, USA) presented the 3-year follow-up outcomes of the SPIRIT-P2 trial [1-3].
The 156-week, phase 3 SPIRIT-P2 study included patients who met the Classification Criteria for Psoriatic Arthritis (CASPAR) and had an inadequate response or intolerance to 1 or 2 TNFi. Although there was a placebo group through week 24, this data was derived only from patients in the intent-to-treat population randomised to ixekizumab at baseline. The 244 participants were randomised to 80 mg subcutaneous ixekizumab every 2 (Q2W; n=123) or 4 weeks (Q4W...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Adalimumab added to methotrexate yields better results in PsA than methotrexate escalation Next Article
Positive effect denosumab on fall risk »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.